检索结果-南通市图书馆

Comparative Study on the Efficacy of tiotropium Bromide Inhalation and Oral Doxofylline Treatment of Moderate to Severe Stable Chronic Obstructive Pulmonary Disease

引用

Journal of Huazhong University of Science and Technology(Medical Sciences) 2011年第5期31卷 614-618页

作者：汪涛罗光伟胡轶李发久马静王坚苗左鹏熊维宁刘先胜赵建平熊盛道张珍祥李承红赵苏孙洁民徐永健 Department of Respiratory Medicine Tongji Hospital Tongji Medical College Huazhong Science and Technology University Department of Respiratory Medicine Wuhan First Hospital Department of Respiratory Medicine Wuhan Second Hospital Department of Respiratory Medicine Wuhan Sixth Hospital

This study compared the efficacy and safety of tiotropium bromide inhalation powder （spiriva） and doxofylline oral tablet （doxofylline） in the treatment of chronic obstructive pulmonary disease （COPD）. A multi-center, randomized, double-blind, double-dummy, parallel-controlled study involved 127 eligible stable moderate to severe COPD patients treated with inhaled tiotropium dry powder （18 μg/day） or oral doxofylline tablets （0.2 g/time, 2 times a day） for 12 and 24 weeks. Before and after treatment for 12 weeks and 24 weeks, respectively, pulmonary function, 6-min walking distance and dyspnea index were recorded. The results showed that in both tiotropium group and doxofylline groups, after 12-week treatment, FEV1, FEV1/FVC% and 6-min walk distance were sig-nificantly higher than those before the medication, while dyspnea index decreased as compared with that before treatment. After 24-week treatment, a slight improvement in the measures was observed as compared with that of 12-weeks treatment, but the difference was not statistically significant. With both 12-week and 24-week treatment, the effect of tiotropium was slightly better than that of doxofylline tablets, with the difference being statistically insignificant. The major adverse events in the tiotropium group and doxofylline group were observed in 9 cases （9.9%） and 12 cases （12.9%）, respectively, and no statistically significant difference was found between them. We are led to conclude that both tiotropium at 18 μg a day and doxofylline tablets at 0.2 g/day （two times a day） are effective and safe for the treatment of COPD.

关键词： chronic obstructive pulmonary disease (COPD) tiotropium doxofylline 6-min walk distance safety

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Effect of Inhaled tiotropium as the Perioperative Management of Patients Undergoing Pulmonary Resection for Primary Lung Cancer

引用

Journal of Cancer Therapy 2014年第9期5卷 845-859页

作者： Takanori Ayabe Masaki Tomita Eiichi Chosa Katsuya Kawagoe Kunihide Nakamura Department of Surgery II Faculty of Medicine University of Miyazaki Miyazaki Japan

Background: The purpose of this study was to evaluate the effectiveness of perioperative tiotropium therapy for patients undergoing pulmonary resection for primary lung cancer. The short-term tiotropium effect was investigated by perioperative pulmonary function and “lung age”. Methods: The fifty-five patients who underwent a lobectomy and had tiotropium treatment available from October 2007 through May 2009 were the subjects. The patients were divided into 3 groups according to their airway limitation such as Chronic Obstructive Pulmonary Disease (COPD) or a history of smoking;those with COPD (%FEV1 ≤70%, C-group, n = 22), smokers (%FEV1 > 70%, S-group, n = 10) and non-smokers (%FEV1 > 70%, N-group, n = 23). As the bronchodilator groups, the C- and S-groups received inhaled tiotropium bromide (18 μg once daily) for 1 week before surgery until at least 3 weeks after surgery without interruption, and as a control, the N-group had no treatment. The preoperative baselines, the predicted postoperative values, and the actual postoperative ones were measured by the pulmonary function test. The changed rates were calculated and denoted as ΔVC, ΔFEV1, ΔVC%, and ΔFEV1/FVC, from the baseline of the predicted postoperative values. The mean “real age” and “lung age” were calculated. Results: In the S-group, the parameters of ΔVC, ΔFEV1, ΔVC%, and ΔFEV1/FVC significantly increased compared to those of the N-group. In the C-group, the increased extents of ΔFEV1 and ΔFEV1/FVC were lower compared to those in the S-group (not significant). In the N-group, the parameters of ΔVC, ΔFEV1, and ΔVC% decreased. The postoperative “lung age” and “real age” were increased to 29.5 ± 18.0 year-old in the C-group, 25.8 ± 18.0 in the S-group, and 24.7 ± 17.0 in the N-group. Lung resection affected the “lung age”;the aging was a 28.9 ± 12.7 year-old increase in the N-group. In the C- and S-group, the “lung age” was a 14-year-old increase. The effect of tiotropium treatment affected the “lung age”

关键词： tiotropium Pulmonary Function Lung Age Lobectomy Lung Cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Clinical effect of tiotropium bromide on pulmonary function,arterial blood gas and serum inflammatory cytokine in elderly patients with COPD at stable stage

引用

Journal of Hainan Medical University 2018年第22期24卷 9-12页

作者： Xiang Deng Xiong-Ping Zhou Zai-Hui Jiang Infectious Diseases Department Jiangxia First People's Hospital of Wuhan CityWuhan430200China

Objective: To observe the clinical effect of tiotropium bromide in elderly patients with COPD at stable stage and its effects on pulmonary function,blood and serum inflammatory cytokine. Methods: 80 elderly patients with COPD s at stable stage were randomly divided into treatment group and control group with 40 patients in each group. The control group was treated with normal treatment. The treatment group was treated with tiotropium bromide on the basis of control group. 3 months after treatment, the pulmonary function、arterial blood gas and serum inflammatory cytokine were detected and compared in the two groups. Results:There was no significant difference in lung function index and TNF- alpha level between the two groups before treatment (P>0.05). The levels of FVC, FEV1% and PEF were increased and serum TNF-α was decreased significantly after treatment in two groups (P0.05);In addition, there were no significant difference in the level of PCT, PaO2, PaCO2 and PaO2/FiO2 after treatment in control group, but the level of PCT and PaCO2 were higher and PaO2 and PaO2/FiO2 were lower obviously after treatment (Ptiotropium bromide can improve pulmonary function, pulmonary function、arterial blood gas and serum inflammatory cytokine in elderly stable COPD patients.

关键词： tiotropium bromide COPD Pulmonary function Arterial blood gas Serum inflammatory cytokine

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

长效吸入型支气管扩张药噻托溴铵tiotropium bromide

引用

中国医药技术与市场 2007年第4期7卷 53-54页

本品由德国勃林格殷格翰（Boehringer IngeIheim）公司研发，与辉瑞（Pfizer）公司共同销售，2002年6月首次在荷兰和菲律宾上市。

关键词：长效吸入型支气管扩张药 tiotropium 噻托溴铵菲律宾

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Therapeutic Effect Observation of tiotropium Bromide in the Treatment of Overlap Syndrome

引用

Journal of Advances in Medicine Science 2020年第1期3卷 15-17页

作者： Yunchao Huang Ting Wang Department of Pulmonary and Critical Care Medicine The Second People’s Hospital of Yunnan ProvinceKunmingYunnan650021China The First Affiliated Hospital of Kunming Medical University KunmingYunnan650032China

Objective:To study the M receptor blocker on inhalation in patients with overlap syndrome(chronic obstructive pulmonary disease and Obstructive sleep apnea syndrome)curative effect ***:25 patients with overlap syndrome as the experimental group,chronic obstructive pulmonary disease patients(30)as control group,patients with overlap syndrome use inhaled tiotropium powder treat 30 days,to observe the changes of pulmonary function,polysomnography,and other indicators after ***:Overlap syndrome were treated by tiotropium bromide inhalation powder,has improved the pulmonary function,the sleep apnea index and lowest nocturnal oxygen saturation after ***:tiotropium bromide has a preferable effective in treatment of overlap syndrome,COPD and OSAHS are interacting with each other.

关键词： Overlap syndrome COPD OSAHS tiotropium

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

tiotropium联合ICS/LABA治疗重度哮喘可显著改善肺功能

引用

海南医学 2012年第20期23卷 98-98页

对哮喘患者使用标准方案进行常规治疗后，仍有接近半数的患者伴有哮喘症状，甚至伴有哮喘急性发作。近期Ker-stjens等报道，对使用吸入糖皮质激素（ICS）和长效β受体激动剂（LABA）治疗后仍伴有哮喘症状的患者，使用噻托溴铵雾化吸入（... 详细信息

对哮喘患者使用标准方案进行常规治疗后，仍有接近半数的患者伴有哮喘症状，甚至伴有哮喘急性发作。近期Ker-stjens等报道，对使用吸入糖皮质激素（ICS）和长效β受体激动剂（LABA）治疗后仍伴有哮喘症状的患者，使用噻托溴铵雾化吸入（tiotropium）每天一次，可显著改善肺功能和减少哮喘急性发作。

关键词： tiotropium 常规治疗肺功能重度哮喘 LABA ICS 长效β受体激动剂哮喘急性发作

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

tiotropium关键词：卒中风险

引用

中国处方药 2008年第3期7卷 22-22页

美国FDA近日向临床医师发生警示，勃林格殷格翰公司生产的慢性阻塞性肺病（COPD）治疗药Spiriva可能会增加病人出现卒中的风险。

关键词： tiotropium 风险卒中关键词 Spiriva 慢性阻塞性肺病美国FDA 临床医师

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

慢阻性肺病的治疗对tiotropium和Salmeterol新的比较研究

引用

德国临床用药 2001年第4期4卷 23-23页

2001年9月24日,在柏林召开的欧洲呼吸道疾病协会年会上介绍了一项长程临床研究.根据Boehringer Ingelheim公司和Pfizer公司的资讯,tiotropium(spiriva )在慢阻性肺病(DOPD)的治疗中被证实是卓有疗效的,甚至比长效β受体激动剂沙美特罗... 详细信息

2001年9月24日,在柏林召开的欧洲呼吸道疾病协会年会上介绍了一项长程临床研究.根据Boehringer Ingelheim公司和Pfizer公司的资讯,tiotropium(spiriva )在慢阻性肺病(DOPD)的治疗中被证实是卓有疗效的,甚至比长效β受体激动剂沙美特罗更有效.

关键词：慢性阻塞性肺疾病药物治疗 tiotropium Salmeterol 比较

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

长效抗胆碱能新药tiotropium即将上市

引用

世界临床药物 2002年第3期23卷 184-184页

作者：崔银珠

Boehringer Ingelheim公司开发的治疗慢性阻塞性肺病的抗胆碱能新药tiotropium计划于2002年初上市。这是第一个每日吸入1次长效支气管扩张药。

关键词：抗胆碱能 tiotropium 新药

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

每日一次tiotropium治疗稳定期慢性阻塞性肺疾病的疗效

引用

国外医学（呼吸系统分册） 2001年第4期21卷 223-223页

作者：康卫国

为了研究tiotropium的支气管扩张效果和安全性,用安慰剂对照,对470例稳定期的慢性阻塞性肺疾病患者进行了研究。他们平均预计值FEV_1=38.6％。其中279例用tiotropium 18μg;191例用安慰剂。均为每日1次,用乳糖干粉吸入器吸入。结果用... 详细信息

为了研究tiotropium的支气管扩张效果和安全性,用安慰剂对照,对470例稳定期的慢性阻塞性肺疾病患者进行了研究。他们平均预计值FEV_1=38.6％。其中279例用tiotropium 18μg;191例用安慰剂。均为每日1次,用乳糖干粉吸入器吸入。结果用药后第1、8、50和92天用肺量计检查,于用药后3小时和23～24小时作为检查时问。结果用tiotropium可显著改善用药后23～24小时的FEV_1和FVC,8天时测量比基线平均增加12％,并能维持至50～92天。用药后平均FEV_1于第1天比基线增加16％,第92天增加20％;FVC于第1天增加17％,第92天增加19％,tiotropium比安慰剂效果显著较大(P<0.0001)。

关键词：慢性阻塞性肺疾病 tiotropium 治疗安慰剂肺疾病

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：